Abstract
Temporary control of platelet reactivity is potentially desirable in a number of clinical settings including cardiopulmonary bypass, dialysis, and long-term extracorporeal circulation. Of those agents currently available which provide antiplatelet therapy, only the prostaglandins offer the dual advantages of potency and rapid reversibility. Consequently, we evaluated the relative potency of three: Prostaglandin E1 (PGE1), Prostacyclin (PGI2), and Iloprost. In addition, we attempted to find insights into the mechanisms of their action with the hope of determining the ideal control agent.
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
References
Schillinger E, Losert W (1980) Identification of PGI2 receptors and cAMP levels in platelets and femoral arteries. Acta Ther 6 (Suppl) abstract 61, p 37
Addonizio VP Jr., Fisher CA, Jenkin BK, Strauss III JF, Musial JF, Edmunds LH (1985) Iloprost (ZK 36 374), a stable analogue of prostacyclin, preserves platelets during simulated extracorporeal circulation. J Thorac Cardiovasc Surg 89: 926–933
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag, Berlin Heidelberg
About this paper
Cite this paper
Fisher, C.A., Reiser, H.J., Addonizio, V.P. (1987). Preliminary Comparison of the Effects of Iloprost, Prostacyclin (PGI2) and Prostaglandin E1 (PGE1) on Human Platelet Function. In: Gryglewski, R.J., Stock, G. (eds) Prostacyclin and Its Stable Analogue Iloprost. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71499-3_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-71499-3_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-71501-3
Online ISBN: 978-3-642-71499-3
eBook Packages: Springer Book Archive